SAN DIEGO, CA, USA I March 5, 2025 I Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback